Publications by authors named "Jacques Delarge"

Claim this Profile
T
Thromboxane A2 inhibition: therapeutic potential in bronchial asthma.
Jean-Michel Dogné, Xavier de Leval, Patricia Benoit, Jacques Delarge, Bernard Masereel

Am J Respir Med· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New pyridobenzodiazepine derivatives: modifications of the basic side chain differentially modulate binding to dopamine (D(4.2), D(2L)) and serotonin (5-HT(2A)) receptors.
Jean-François Liégeois, Laurence Eyrolles, Bart A Ellenbroek, Christel Lejeune, Pascal Carato, Jacques Delarge

J Med Chem· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and biological evaluation of aroylguanidines related to amiloride as inhibitors of the human platelet Na(+)/H(+) exchanger.
Didier Laeckmann, Françoise Rogister, Jean Victor Dejardin, Christelle Prosperi-Meys, Joseph Géczy, Jacques Delarge

Bioorg Med Chem· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New trends in dual 5-LOX/COX inhibition.
Xavier de Leval, Fabien Julemont, Jacques Delarge, Bernard Pirotte, Jean-Michel Dogne

Curr Med Chem· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent advances in antiplatelet agents.
Jean-Michel Dogne, Xavier de Leval, Patricia Benoit, Jacques Delarge, Bernard Masereel

Curr Med Chem· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal effects of JL 13, a pyridobenzoxazepine derivative with an antipsychotic potential, on circulating prolactin levels in male rats.
Jean-François Liégeois, Jacques Bruhwyler, Jean-Claude Hendrick, Jacques Delarge, Jean-Jacques Legros

Neurosci Lett· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis